

Acute Leukaemia

Dr Andrew Wilson
Consultant Haematologist
UCLH, London

British Society for Haematology
Listening • Learning • Leading

Outcomes

- Describe the common signs and symptoms of acute leukaemia
- Outline how leukaemia is diagnosed
- Discuss the management of AML & APL

British Society for Haematology
Listening • Learning • Leading

Case

- Mr Adams is a 27 year old who attends A&E due to tiredness and new bruising which has developed over his body. On examination, he has a temperature of 37.8^{o}C and is covered in a petechial rash. Urgent bloods are sent which show:

British Society for Haematology
Listening • Learning • Leading

Full blood count

FULL BLOOD COUNT				
White Cell Count	*	1.30	10^9/L	3.2 - 10.5
RBC	*	2.84	10^{12}/L	3.9 - 5.4
Haemoglobin	*	67	g/L	130 - 169
Haematocrit	*	0.24		0.364 - 0.481
MCV	*	107.7	fl	81 - 100
MCH		28.3	pg	27.3 - 34.8
Platelets	*	21	10^9/L	120 - 400
WBC DIFFERENTIAL				
Neutrophils	*	0.10	10^9/L	1.5 - 7.2
Lymphocytes	*	0.50	10^9/L	0.8 - 3.1
Monocytes		0.70	10^9/L	0.2 - 1
Eosinophils	*	0.01	10^9/L	0.02 - 0.5
Basophils	*	0.00	10^9/L	0.02 - 0.5

British Society for Haematology
Listening • Learning • Leading

Blood film



British Society for Haematology
Listening • Learning • Leading

Question

What is the next most important test to request?

A) Blood film
B) Coagulation screen
C) Fibrinogen
D) LFTs
E) U&Es

British Society for Haematology
Listening • Learning • Leading

- The haematology registrar on-call looks at the film and suspects acute myeloid leukaemia (AML).

British Society for Haematology
Listening • Learning • Leading

What's in a name?

- *Leukos* – White *aemia* – Blood
- There are many types!

- **Acute** – aggressive, rapidly fatal, usually either myeloid or Lymphoid (occasionally mixed)

- **Chronic** – more indolent, may not require immediate treatment – we are not going to cover these

British Society for Haematology
Listening • Learning • Leading

Classification of Leukaemias

Acute

Acute Myeloid Leukaemia (AML)
    Acute Promyelocytic Leukaemia (APL/APML)
Acute Lymphoblastic Leukaemia (ALL)
Mixed phenotype Acute Leukaemia (MPAL)
Lymphoblastic Lymphoma (LBL)

Chronic

Chronic Myeloid Leukaemia (CML)
Chronic Neutrophilic Leukaemia (CNL)

[Lymphoma]

Hairy Cell Leukaemia (HCL)
Chronic Lymphocytic Leukaemia (CLL)
Large Granular Lymphocytic Leukaemia (LGLL)

British Society for Haematology
Listening • Learning • Leading

AML



British Society for Haematology
Listening • Learning • Leading

ALL



British Society for Haematology
Listening • Learning • Leading

Normal haematopoiesis



Normal haematopoiesis and the concept of stem cell transplantation

British Society for Haematology
Listening • Learning • Leading

What happens in Acute Leukaemia?



JIN, L., WU, L.. Recent Advances in Characterization of Pre-Leukemic/Leukemic Stem Cells in Acute Myeloid Leukemia. Cellular and Molecular Medicine Research, North America, 1, jan. 2018. Available at: <http://www.thecmmr.org/index.php/cmmr/article/view/26/31>.

British Society for Haematology
Listening • Learning • Leading

Clinical features of acute leukaemia

- Bone marrow failure
- Tiredness and fatigue
- Infection (often life-threatening)
- Bleeding and bruising
- Hyperleukocytosis (often life-threatening)
- DIC (often life-threatening = esp APML)
- Gum hypertrophy (esp monoblastic leukaemia)

British Society for Haematology
Listening • Learning • Leading

Bone marrow examination



British Society for Haematology
Listening • Learning • Leading

Diagnosis of Acute Leukaemia





www.abcam.com

British Society for Haematology
Listening • Learning • Leading



Behm, F.G. (2003). Classification of Acute Leukemias.

- Mr Adams wants to know his chances of survival.
- What would you tell him?

British Society for Haematology
Listening • Learning • Leading

G-banding



British Society for Haematology
Listening • Learning • Leading

What's the abnormality?



British Society for Haematology
Listening • Learning • Leading



David Grimwade et al. Blood 2010;116:354-365

British Society for Haematology
Listening • Learning • Leading

Risk category*	Genetic abnormality
Favorable	t(8;21)(q22;q22.1); *RUNX1-RUNX1T1*
	inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*
	Mutated *NPM1* without *FLT3*-ITD or with *FLT3*-ITD^{low}†
	Biallelic mutated *CEBPA*
Intermediate	Mutated *NPM1* and *FLT3*-ITD^{high}†
	Wild-type *NPM1* without *FLT3*-ITD or with *FLT3*-ITD^{low}† (without adverse-risk genetic lesions)
	t(9;11)(p21.3;q23.3); *MLLT3-KMT2A*‡
	Cytogenetic abnormalities not classified as favorable or adverse
Adverse	t(6;9)(p23;q34.1); *DEK-NUP214*
	t(v;11q23.3); *KMT2A* rearranged
	t(9;22)(q34.1;q11.2); *BCR-ABL1*
	inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); *GATA2,MECOM(EVI1)*
	−5 or del(5q); −7; −17/abn(17p)
	Complex karyotype,§ monosomal karyotype‖
	Wild-type *NPM1* and *FLT3*-ITD^{high}†
	Mutated *RUNX1*¶
	Mutated *ASXL1*¶
	Mutated *TP53*#

Döhner, H et al. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*, *129*(4), 424–447. https://doi.org/10.1182/blood-2016-08-733196



Jacob M. Rowe, and Martin S. Tallman Blood 2010;116:3147-3156

British Society for Haematology
Listening • Learning • Leading

What is in AML chemotherapy?

- Combination of agents
- Myelotoxic (pancytopenia for ~24 days
- Causes profound immunosuppression
- Mucositis
- Given in cycles (usually 3-4 in total)
- Usually 4-6 week inpatient stay
- Some patients require bone marrow transplantation

British Society for Haematology
Listening • Learning • Leading

How does SACT work?



From: *Essential Haematology*, 6th Edn. © A. V. Hoffbrand & P. A. H. Moss. Published 2011 by Blackwell Publishing Ltd.

British Society for Haematology
Listening • Learning • Leading

How do we treat AML?

- Curative intent (usually 3-4 cycles)

Daunorubicin and **A**ra-C (DA3+10) +/-
Gemtuzumab ozogamicin (GO; anti-CD33 mAb)
Midostaurin (FLT3 inhibitor)

Fludarabine, **G**CSF, **A**ra C and **Ida**rubicin (Flag-Ida)

CPX-351 (liposomal formulation of DA)

- Palliative intent (continue until progression)

Azacytidine +/- Venetoclax (BCL2 inhibitor)

Low dose Ara-C

Gilteritinib (FLT3 inhibitor)

Best supportive care

British Society for Haematology
Listening • Learning • Leading

How does SACT work? (Signalling inhibitors)



Cancers 2018, 10(6), 155; https://doi.org/10.3390/cancers10060155

British Society for Haematology
Listening • Learning • Leading



From: *Essential Haematology*, 6th Edn. © A. V. Hoffbrand & P. A. H. Moss.
Published 2011 by Blackwell Publishing Ltd.

ALL chemotherapy

- Steroid backbone
- Vincristine
- Daunorubicin
- Intrathecal methotrexate
- HD methotrexate
- Ara-C
- Pegylated asparaginase

British Society for Haematology
Listening • Learning • Leading

Acute promyelocytic leukaemia

- Chromosomal translocation (t15;17) creating the PML-RARa fusion protein
- The fusion protein causes maturation arrest and accumulation of abnormal promyelocytes which leads to life-threatening DIC
- This is a **haematological emergency**
- Treatment with *all*-trans retinoic acid should commence as soon as the diagnosis is suspected.

British Society for Haematology
Listening • Learning • Leading

Bone marrow smear



British Society for Haematology
Listening • Learning • Leading

Immediate treatment

- Keep plts >50x10^9/L
- Keep fibrinogen >1.5g/L
- Do not leukopherese
- ATRA relieves differentiation block
- Add arsenic trioxide (ATO) or anthracycline chemotherapy

Complications of treatment

- Early intracranial haemorrhage (first 48 hrs) often fatal
- Long QT syndrome (if ATO used)
- ATRA differentiation syndrome (occurs at 7-10 days)

British Society for Haematology
Listening • Learning • Leading

A historical view of the treatment outcome
(represented by 5-year overall survival) of APL.



Sai-Juan Chen et al. Blood 2011;117:6425-6437

British Society for Haematology
Listening • Learning • Leading

Outcomes

- Describe the common signs and symptoms of acute leukaemia
- Outline how leukaemia is diagnosed
- Discuss the management of AML & APL

British Society for Haematology
Listening • Learning • Leading